0001209191-21-008101.txt : 20210205
0001209191-21-008101.hdr.sgml : 20210205
20210205164357
ACCESSION NUMBER: 0001209191-21-008101
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210203
FILED AS OF DATE: 20210205
DATE AS OF CHANGE: 20210205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arbuckle Stuart A
CENTRAL INDEX KEY: 0001557290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 21596614
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-03
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001557290
Arbuckle Stuart A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Chief Commercial Officer
Common Stock
2021-02-03
4
A
0
8438
0.00
A
43617
D
Common Stock
2021-02-03
4
A
0
12388
0.00
A
56005
D
Common Stock
2021-02-03
4
A
0
13952
0.00
A
69957
D
Common Stock
2021-02-03
4
M
0
1554
86.52
A
71511
D
Common Stock
2021-02-03
4
S
0
148
211.22
D
71363
D
Common Stock
2021-02-03
4
S
0
488
212.77
D
70875
D
Common Stock
2021-02-03
4
S
0
497
213.90
D
70378
D
Common Stock
2021-02-03
4
S
0
242
214.98
D
70136
D
Common Stock
2021-02-03
4
S
0
90
215.80
D
70046
D
Common Stock
2021-02-03
4
S
0
89
216.83
D
69957
D
Common Stock
140
I
401(k)
Stock Option (Right to Buy)
86.52
2021-02-03
4
M
0
1554
0.00
D
2027-02-02
Common Stock
1554
0
D
Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021.
Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest in installments beginning on 02/10/2021.
Restricted stock unit award that vests in installments beginning on 02/17/2022.
Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $211.22 (range $211.06 to $211.27).
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $212.77 (range $212.29 to $213.20).
Open market sales reported on this line occurred at a weighted average price of $213.90 (range $213.49 to $214.17).
Open market sales reported on this line occurred at a weighted average price of $214.98 (range $214.72 to $215.36).
Fully vested.
/s/ Sabrina Yohai, Attorney-in-Fact
2021-02-05